Twist Bioscience Corp. (TWST)
140.74
-4.85
(-3.33%)
USD |
NASDAQ |
Aug 24, 16:00
138.00
-2.74
(-1.95%)
After-Hours: 20:00
Twist Bioscience Enterprise Value : 9.051B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 9.051B |
| August 20, 2026 | 8.471B |
| August 19, 2026 | 8.851B |
| August 18, 2026 | 7.203B |
| August 17, 2026 | 7.724B |
| August 14, 2026 | 7.358B |
| August 13, 2026 | 7.779B |
| August 12, 2026 | 7.774B |
| August 11, 2026 | 7.643B |
| August 10, 2026 | 7.753B |
| August 07, 2026 | 7.176B |
| August 06, 2026 | 6.763B |
| August 05, 2026 | 7.135B |
| August 04, 2026 | 6.159B |
| August 03, 2026 | 6.261B |
| July 31, 2026 | 5.665B |
| July 30, 2026 | 5.651B |
| July 29, 2026 | 5.283B |
| July 28, 2026 | 5.477B |
| July 27, 2026 | 5.351B |
| July 24, 2026 | 5.584B |
| July 23, 2026 | 5.720B |
| July 22, 2026 | 5.831B |
| July 21, 2026 | 5.935B |
| July 20, 2026 | 5.408B |
| Date | Value |
|---|---|
| July 17, 2026 | 5.809B |
| July 16, 2026 | 5.644B |
| July 15, 2026 | 5.731B |
| July 14, 2026 | 5.726B |
| July 13, 2026 | 5.589B |
| July 10, 2026 | 5.607B |
| July 09, 2026 | 5.797B |
| July 08, 2026 | 5.529B |
| July 07, 2026 | 5.632B |
| July 06, 2026 | 6.190B |
| July 02, 2026 | 6.147B |
| July 01, 2026 | 6.335B |
| June 30, 2026 | 6.375B |
| June 29, 2026 | 6.038B |
| June 26, 2026 | 6.130B |
| June 25, 2026 | 5.931B |
| June 24, 2026 | 5.602B |
| June 23, 2026 | 5.207B |
| June 22, 2026 | 5.218B |
| June 18, 2026 | 5.366B |
| June 17, 2026 | 5.075B |
| June 16, 2026 | 5.204B |
| June 15, 2026 | 4.946B |
| June 12, 2026 | 4.658B |
| June 11, 2026 | 4.527B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 2.168B |
| Prime Medicine, Inc. | 630.11M |
| Intellia Therapeutics, Inc. | 1.433B |
| 10X Genomics, Inc. | 8.011B |
| Generate Biomedicines, Inc. | 1.673B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.05M |
| Revenue (Quarterly) | 118.38M |
| Total Expenses (Quarterly) | 153.43M |
| EPS Diluted (Quarterly) | -0.5617 |
| Gross Profit Margin (Quarterly) | 52.76% |
| Profit Margin (Quarterly) | -29.61% |
| Earnings Yield | -1.58% |
| Normalized Earnings Yield | -1.522 |